Children and teens aged 12 to 17 years who have hepatitis C virus (HCV) infection will have access to the same antiviral medications that are known to eliminate HCV infections in adults.
Sofosbuvir, marketed as Solvadi, and a combination of sofosbuvir and ledipasvir, marketed as Harvoni, are the first direct-acting antiviral treatments to gain FDA approval for pediatric patients with HCV infection. Direct-acting antivirals decrease HCV levels by preventing the virus from replicating. In most cases, FDA officials said, the drugs cure HCV infection.
Voelker R. A First in HCV Drugs for Youths. JAMA. 2017;317(19):1942. doi:10.1001/jama.2017.5542
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: